Macular Degeneration Treatment via Stem Cell Mutation Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches to addressing age-related macular degeneration, particularly geographic atrophy, lack effective early detection methods and preventive therapies, and existing genetic studies have failed to identify significant mutations contributing to late-onset disease.
Innovation Solution
The method involves obtaining biological samples to determine mutations in nuclease hypersensitive regions or transcriptional regulatory regions of retinal genes, specifically PRDM13, and administering retinal cells, progenitor cells, or pluripotent stem cells lacking these mutations to treat, prevent, or restore macular degeneration by forming or rebuilding the macula lutea.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If stem cell transplantation is used to rebuild the macula, then macular repair capability is improved, but treatment complexity and cost increase
Solution Approach 1:
The patent performs genetic screening and mutation analysis before stem cell transplantation to identify suitable candidates and select appropriate cell sources. This preliminary genetic characterization ensures that the transplanted stem cells lack the pathogenic mutations present in the patient's native retinal cells, thereby preventing recurrence of the disease while maximizing therapeutic benefit.
2Manufacturing precision
If genetic screening is performed to identify mutations, then treatment precision is improved, but diagnostic time and cost increase
Solution Approach 1:
The patent replaces traditional labor-intensive genetic screening methods with automated next-generation sequencing technology. This substitution enables comprehensive analysis of multiple candidate genes simultaneously, dramatically reducing both the time required for genetic characterization and the cost per test while maintaining high precision in mutation detection.
3Duration of action of stationary object
If early intervention is implemented, then disease progression is slowed, but accessibility and ease of operation decrease
Solution Approach 1:
The patent divides the macular degeneration treatment into distinct stages: (1) genetic screening and risk assessment, (2) stem cell source selection and preparation, and (3) targeted transplantation. This segmentation allows for systematic early intervention while making each individual step more manageable and accessible to healthcare providers and patients.
Data Source
AI summary
The present invention relates to compositions and methods for treating, screening and diagnosing macular degeneration in a subject. This is a new pathway found which is the only one known to be involved in development of the human macula. Manipulation and control of this pathway will allow rebuilding and/or repair of the macula, making new and improved better maculae.